This program is intended for multidisciplinary teams consisting of medical oncologists, radiation oncologists, thoracic oncologists, pulmonologists, surgeons, nurses, pharmacists, and other community healthcare professionals involved in the neoadjuvant or adjuvant treatment of patients with early-stage cancer.
The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in understanding and applying the latest science and clinical trial data on current and emerging immuno-oncology therapies in earlier stages of cancer into clinical practice.
Upon completion of this activity, participants should be able to:
Assess the biologic rationale for the use of immuno-oncology in earlier stages of cancer, considering the available clinical data, impact on tumor natural history, and immune-related implications.
Evaluate clinical trial data and endpoints, including survival surrogates, on the use of immune checkpoint inhibitors as neoadjuvant/adjuvant therapy to inform patients earlier stages of cancer on the potential long-term benefits of this therapeutic strategy
Identify patients with early-stage solid cancers who would be appropriate for treatment or clinical trial enrollment with immune checkpoint inhibitors in the neoadjuvant, adjuvant, or maintenance/consolidation setting based on recurrence risk, surgical considerations, biomarkers, risk–benefit considerations, as well as potential disparities (socio-economic, racial, and age) in care
Identify and manage common and serious immune-related adverse events associated with immuno-oncology agents in early stages of cancer
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Patrick Forde, MBBCh
Director, Thoracic Oncology Research Program
Johns Hopkins University
Patrick Forde, MBBCh: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, F Star, G1 Therapeutics, Genentech, Gritstone, iTeos, Janssen, Novartis, Regeneron, Sanofi, Surface, Synthekine; researcher: AstraZeneca, BioNTech, Bristol Myers Squibb, Novartis, Regeneron.
Heather McArthur, MD, MPH
Department of Medicine
Komen Distinguished Chair in Clinical Breast Cancer
Clinical Director Breast Cancer Program
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Heather McArthur MD, MPH: consultant/advisor: AstraZeneca, Crown Bioscience, Daiichi Sankyo, Gilead, Immunomedics, Merck, Pfizer, Puma, Seattle Genetics.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 24, 2023, through July 23, 2024:
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-189-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.